Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Carrigan

P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Journal of Thoracic Oncology

English

Related publications

P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032

Journal of Thoracic Oncology

English

PD.1.01 Health-Related Quality of Life With Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189

Journal of Thoracic Oncology

English

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Journal of Thoracic Oncology

English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology

English

P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

Journal of Thoracic Oncology

English

P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined With Carboplatin and Pemetrexed (GCP) for NSCLC With EGFR Mutations (NEJ009)

Journal of Thoracic Oncology

English

P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC

Journal of Thoracic Oncology

English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

English

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Carrigan

P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Related publications

P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032

PD.1.01 Health-Related Quality of Life With Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined With Carboplatin and Pemetrexed (GCP) for NSCLC With EGFR Mutations (NEJ009)

P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial